Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p24CE DNA Vaccine in HIV-Infected Persons on ART
NCT03560258Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of p24CE DNA vaccine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2019; status: completed.
02
Drugs
p24CE DNA vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03560258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03560258.